Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial
Marco Venturini(Ente Ospedaliero Ospedali Galliera), Paolo Bruzzi(Alleanza Contro il Cancro), C. Caroti(Ente Ospedaliero Ospedali Galliera), P. Pronzato(Accademia Nazionale dei Lincei), Giuseppe Canavese(Ente Ospedaliero Ospedali Galliera), Lucia Del Mastro(Ospedale Policlinico San Martino), Fulvio Brema(Ente Ospedaliero Ospedali Galliera), Franco Testore(Ente Ospedaliero Ospedali Galliera), Editta Baldini, Riccardo Rosso(Ente Ospedaliero Ospedali Galliera), Mario Roberto Sertoli(Ente Ospedaliero Ospedali Galliera), A. Contu(Ente Ospedaliero Ospedali Galliera), Enrico Aitini, Giovanna Cavazzini(University of Padua)
Cited by 154
Related Papers
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Trends and challenges in the operation of pumped-storage hydropower plants
|Renewable and Sustainable Energy Reviews|2015|315
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype
|Cancer Treatment Reviews|2018|282
A new generation of small hydro and pumped-hydro power plants: Advances and future challenges
|Renewable and Sustainable Energy Reviews|2014|273